Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
spinal muscular atrophy
Pharma
Scholar Rock scores its first FDA approval for SMA treatment
The treatment, which is set to “ship in the coming days” is projected to cost $310,000 annually.
Donavyn Coffey
Sep 14, 2026 10:37am
Novo’s Catalent plant ditched in FDA refiling of SMA drug
Aug 10, 2026 10:06am
Biogen launches ‘Ready for More’ HD Spinraza campaign
Jun 26, 2026 8:17am
Novartis teams with Becoming rentABLE for its new SMA campaign
Jun 25, 2026 8:38am
Biogen bets HD Spinraza can outmuscle Roche's oral rival
Feb 6, 2026 12:02pm
Novartis scores FDA approval for new version of SMA gene therapy
Nov 25, 2025 10:02am
